Datasets: Eye tracking to explore attendance in health-state descriptions

A crucial assumption in health valuation methods is that respondents pay equal attention to all information components presented in the response task. So far, there is no solid evidence that respondents are fulfilling this condition. The aim of our study is to explore the attendance to various information cues presented in the discrete choice (DC) response tasks. Eye tracking was used to study the eye movements and fixations on specific information areas. This was done for seven DC response tasks comprising health-state descriptions. A sample of 10 respondents participated in the study. Videos of their eye movements were recorded and are presented graphically. Frequencies were computed for length of fixation and number of fixations, so differences in attendance were demonstrated for particular attributes in the tasks. The data is produced by the software Gazepoint and stored in the Gazepoint format. The relevant data underlying the graphs can be provided as simple Excel file, or SigmaPlot Graph. For full reproducibility the data of participants’ eye-movements, the data being held in Gazepoint format is required. However, due to anonymity of participants the videos are not provided. The eye-movements of the respondents were recorded using specific software Gazepoint. Therefore, for getting the full data, it will be needed to install the Gazepoint Analysis software and access the underlying data from the author

Towards assessing the preferred usage features of upper limb prostheses: most important items regarding prosthesis use in people with major unilateral upper limb absence—a Dutch national survey

To determine which items regarding prosthesis use were considered most important by adults with major unilateral upper limb absence (ULA) and to develop a patient-reported outcome measure to assess the preferred usage features of upper limb prostheses: PUF-ULP. Based on a qualitative meta-synthesis combined with input from patients and clinicians a graphical diagram of 79 items related to prosthesis use was developed. Adults with ULA (N = 358; mean age = 55.4 ± 16.5 years; 52.0% male/40.8% female/7.3% unknown) selected their top-10 of most important items from this diagram. This study is registered in the Netherlands Trial Register: NL7682. Most selected items were “wearing comfort” (54.0% of cases), “grabbing, picking up, and holding” (34.3%), and “weight” (31.4%). All subpopulations (i.e. age, sex, origin of ULA, level of ULA, and prosthesis type), except multi-grip myoelectric hand prosthesis users (MHP), selected “wearing comfort” most. Nine items were included in the PUF-ULP: “wearing comfort,” “functionality,” “independence,” “work, hobby, and household,” “user-friendly,” “life-like appearance,” “phantom limb pain,” “overuse complaints,” and “reliability.” All prosthesis users, except MHP-users, considered wearing comfort most important, which might be of interest for future research and industry. The PUF-ULP can be used to reflect the match between users and their prostheses.IMPLICATIONS FOR REHABILITATIONAll persons with upper limb absence, except multi-grip myoelectric hand prosthesis users, considered “wearing comfort” most important regarding prosthesis use, which highlights that prosthesis wearing comfort deserves more attention in future research to increase the value placed by the user on their upper limb prosthesis.Regarding prosthesis use, men considered “ease of control” more important compared to the overall population, while women considered “independence,” “household,” “life-like appearance,” “overuse complaints,” and “anonymity” more important.Persons with a mono- or multi-grip myoelectric upper limb prosthesis rated function-related items as more important compared to the overall population, while persons with a passive/cosmetic prosthesis rated comfort-related and appearance-related items as more important.The newly developed measurement tool, also called the PUF-ULP, provides a single score that represents the match between the user and their upper limb prosthesis. All persons with upper limb absence, except multi-grip myoelectric hand prosthesis users, considered “wearing comfort” most important regarding prosthesis use, which highlights that prosthesis wearing comfort deserves more attention in future research to increase the value placed by the user on their upper limb prosthesis. Regarding prosthesis use, men considered “ease of control” more important compared to the overall population, while women considered “independence,” “household,” “life-like appearance,” “overuse complaints,” and “anonymity” more important. Persons with a mono- or multi-grip myoelectric upper limb prosthesis rated function-related items as more important compared to the overall population, while persons with a passive/cosmetic prosthesis rated comfort-related and appearance-related items as more important. The newly developed measurement tool, also called the PUF-ULP, provides a single score that represents the match between the user and their upper limb prosthesis

Towards assessing the preferred usage features of upper limb prostheses: most important items regarding prosthesis use in people with major unilateral upper limb absence - a Dutch national survey

CSV-file with survey results from people with upper limb absence (N=358) in the Netherlands. In the survey participants were asked to select their 10 most important items regarding prosthesis use from a diagram that contained 79 items (i.e. the HealthFan diagram). Consequently, they were asked to rank those ten items from most important to least important. Six participants did not fulfill the ranking task, in those cases, the selected factors are shown in random order. Due to the small group of people with ULA in the Netherlands, we do not provide any personal details in this dataset. The dataset only contains the top-10 selected items from the participants that were included in the analyses. A codebook to interpret the data was added as a PDF file

Towards assessing the preferred usage features of upper limb prostheses: most important items regarding prosthesis use in people with major unilateral upper limb absence - a Dutch national survey

CSV-file with survey results from people with upper limb absence (N=358) in the Netherlands. In the survey participants were asked to select their 10 most important items regarding prosthesis use from a diagram that contained 79 items (i.e. the HealthFan diagram). Consequently, they were asked to rank those ten items from most important to least important. Six participants did not fulfill the ranking task, in those cases, the selected factors are shown in random order. Due to the small group of people with ULA in the Netherlands, we do not provide any personal details in this dataset. The dataset only contains the top-10 selected items from the participants that were included in the analyses. A codebook to interpret the data was added as a PDF file

Economic analyses of respiratory tract infection diagnostics: a systematic review

This GitHub repository contains code to create the tables as presented in the manuscript

Dataset balance study and renal cation excretion study

Raw data concerning a retrospective study on sodium and fluid balance and an observational study on renal cation excretion in patients with ICU-acquired hypernatremia. These data belong to a yet unpublished manuscript. Once the manuscript is published, the data will be available as open access

Ulipristal acetate for pre-operative treatment of moderate to severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis

Objective: Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate to severe uterine fibroids in women of reproductive age in The Netherlands. The analysis was performed and applied within the framework of the ulipristal acetate submission for reimbursement in 2012. Methods: A decision model was developed to compare the total costs of ulipristal acetate compared to leuprolide, the standard care in The Netherlands. The target population of this study corresponded to the type of patients included in the PEARL II clinical trial; i.e. women of reproductive age requiring pre-operative treatment for uterine fibroids. Sensitivity analysis was implemented, to assess uncertainties. Data regarding costs, effects, and other input parameters were obtained from relevant published literatures, the Dutch Healthcare Insurance Board and expert opinion obtained by means of a panel of experts from several medical centres in The Netherlands. Results: In The Netherlands, the total costs of ulipristal acetate and leuprolide were estimated at €4,216,027 and €4,218,095, respectively. The annual savings of ulipristal acetate were therefore estimated at €2,068. The major driver of this cost difference was the cost of administration for leuprolide. Sensitivity analyses showed that ulipristal acetate mostly remained cost-saving over a range of assumptions. The budget impact analysis indicated that the introduction of ulipristal acetate was estimated to result in cost savings in the first three years following the introduction. The results of this study were used in the decision on reimbursement of ulipristal acetate according to the Dutch Reference Pricing system in 2012. Conclusion: Ulipristal acetate was cost saving compared to leuprolide and has the potential to provide substantial savings on the healthcare budget in The Netherlands

Ulipristal acetate for pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands: cost minimization analysis and budget impact analysis

Objective: Ulipristal acetate has been found to be non-inferior to other pre-operative treatments of uterine fibroids, particularly leuprolide. The objective of this study was to assess the pharmacoeconomic profile of ulipristal acetate compared to leuprolide for the pre-operative treatment of moderate-to-severe uterine fibroids in women of reproductive age in The Netherlands. The analysis was performed and applied within the framework of the ulipristal acetate submission for reimbursement in 2012. Methods: A decision model was developed to compare the total costs of ulipristal acetate compared to leuprolide, the standard care in The Netherlands. The target population of this study corresponded to the type of patients included in the PEARL II clinical trial; i.e. women of reproductive age requiring pre-operative treatment for uterine fibroids. Sensitivity analysis was implemented to assess uncertainties. Data regarding costs, effects, and other input parameters were obtained from relevant published literatures, the Dutch Healthcare Insurance Board, and expert opinion obtained by means of a panel of experts from several medical centers in The Netherlands. Results: In The Netherlands, the total costs of ulipristal acetate and leuprolide were estimated at €4,216,027 and €4,218,095, respectively. The annual savings of ulipristal acetate were, therefore, estimated at €2,068. The major driver of this cost difference was the cost of administration for leuprolide. Sensitivity analyses showed that ulipristal acetate mostly remained cost-saving over a range of assumptions. The budget impact analysis indicated that the introduction of ulipristal acetate was estimated to result in cost savings in the first 3 years following the introduction. The results of this study were used in the decision on reimbursement of ulipristal acetate according to the Dutch Reference Pricing system in 2012. Conclusion: Ulipristal acetate was cost saving compared to leuprolide and has the potential to provide substantial savings on the healthcare budget in The Netherlands

Data from: Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach

Cervical cancer poses a substantial burden in terms of morbidity, mortality, and economic losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer screening among females may reduce the burden of HPV-related diseases, including cervical cancer. However, limited funds may impede the implementation of population-based programmes. Governmental investments in the prevention of infectious disease may have broader economic and fiscal benefits, which are not accounted in conventional economic analyses. This study estimates the broader economic and fiscal impacts of implementing HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the government. A government-perspective quantitative analytic framework was applied to assess the Net Present Value (NPV) of investment on cervical cancer prevention strategies including HPV vaccination, cervical screening and its combination in Indonesia. All monetary values were presented in International Dollars (I$). Based on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indonesian government. The combination of cervical screening and HPV vaccination generated a substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and 19,359, respectively. It was estimated that HPV vaccination in combination with cervical screening is the most favorable option for cervical cancer prevention (NPV I$2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical screening alone (NPV I$375.244.000). Conclusion. In addition to clinical benefits, investing in HPV vaccination and cervical screening may yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits resulting from reduction of cervical cancer-related morbidity and mortality. The data package contains one dataset: - A fiscal analytic model of HPV vaccination in Indonesi

Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach

A fiscal analytic model of HPV vaccination in Indonesi